Clinical ResearchJoin a study
Join a clinical study at OIC
Be part of the research that shapes the future of medicine, with expert care, at no cost to you.
Participation benefits
What you can expect as a participant
- Study medications provided at no cost
- Study-related labs provided at no cost
- Study-related visits provided at no cost
- Monitoring by study-related providers
- Transportation assistance, when needed, through Lyft, Uber, or bus passes
- Stipend provided at each study visit
Now enrolling
Studies currently accepting participants
Merck-011 · Once-Monthly Oral PrEP Study (EXPRESSIVE)
A single tablet, once a month, for HIV prevention. This Phase 3 study evaluates MK-8527, an oral medication taken once monthly as HIV pre-exposure prophylaxis (PrEP) — an alternative to daily pills or injections. Route: Oral tablet, once monthly Length: Screening up to 45 days; treatment phase 30 months with 28-day follow-up Compensation: Stipend provided at each study visit You may pre-qualify if you are HIV-negative and at increased risk of HIV exposure. Contact our team for a confidential pre-screening. Protocol: MK8527-011 · Phase 3 · Sponsor: Merck
I’m interested →ViiV-222794 · QUATRO: Ultra Long-Acting HIV Maintenance
A Phase 3, randomized, multicenter, open-label, non-inferiority study evaluating cabotegravir ultra long-acting plus rilpivirine ultra long-acting (or cabotegravir long-acting plus rilpivirine long-acting) in adults and adolescents with HIV who are virologically suppressed on ART. Route: IM Length: 35 months Compensation: Stipend of $100 for scheduled/unscheduled visits, $200 for complicated visits (screening, baseline, Month 3, Month 7, and pregnancy LTFU), $25 for telephone contacts. Protocol: GSK222794 · Phase 3 · Sponsor: ViiV/GSK
I’m interested →Tell us about you
Pre-screening interest form
Referring a participant?
Are you a provider or community organization? Refer a potential participant to our team and we’ll take care of the rest. Call 407-647-3960 or use the contact form.